The authors compared the utility of the International Prostate Symptom Score (IPSS) and the Japan Orthopaedic Association (JOA) score for evaluating lower urinary tract symptoms (LUTS) associated with cervical degenerative myelopathy.
A total of 128 patients with cervical degenerative myelopathy were assessed according to the IPSS and JOA score. These included 31 females (F-group), 61 males without urinary tract lesions (Mn-group), and 36 males with urinary tract lesions (Mu-group). Patients with >8 points on the IPSS and ≦2 points on the JOA score were classified as LUTS (+). Additionally, we investigated both storage and voiding symptoms using the IPSS. Patients with ≧4 points from a possible maximum of 15 across 3 questions relating to storage and voiding symptoms on the IPSS were defined as symptom (+).
Among all 128 patients, LUTS positivity was detected in 58 patients (45%) by the IPSS and in 52 patients (41%) by the JOA score. In the F-group, 13 (42%) and 10 patients (32%) were LUTS (+) based on the IPSS and JOA score, respectively. In the Mn-group, 23 (38%) and 20 patients (33%) were LUTS (+) based on the IPSS and JOA score, respectively. Thus, there was good correlation between the IPSS and JOA score.
However, a more detailed analysis of the findings revealed that the group defined as normal by the JOA score had worse symptoms on the IPSS : 24% of the 128 patients, including 24% in the F-group and 22% in the Mn-group. In addition, it was revealed that the group defined as slight by the JOA score had a wide range of symptoms from 2 to 27 on the IPSS. Moreover, a significant difference was not observed in IPSS between the slight group and severe groups according to the JOA score.
Also from another viewpoint, IPSS clearly identified many cases with voiding symptoms and many mixed cases with both voiding and storage symptoms associated with cervical degenerative myelopathy.
In conclusion, IPSS was considered to be a more sensitive and useful scoring system than the JOA score for evaluating LUTS associated with cervical degenerative myelopathy.
View full abstract